Pharmaniaga Post-PN17 Betting Big on Biopharma

Pharmaniaga officially exited PN17 status in March, having taken three years to complete its regularisation plan. The firm is now vying to become the most valuable pharmaceutical company in Malaysia by 2030 leveraging on its ongoing government concession in logistics and biopharma manufacturing capabilities. We catch-up with Managing Director Dato’ Zulkifli Jafar to find out how he intends to achieve this goal.See omnystudio.com/listener for privacy information.